BR0307195A - Composições farmacêuticas de mesilato de zoniporide e processos para melhorar a solubilidade do zoniporide - Google Patents

Composições farmacêuticas de mesilato de zoniporide e processos para melhorar a solubilidade do zoniporide

Info

Publication number
BR0307195A
BR0307195A BR0307195-2A BR0307195A BR0307195A BR 0307195 A BR0307195 A BR 0307195A BR 0307195 A BR0307195 A BR 0307195A BR 0307195 A BR0307195 A BR 0307195A
Authority
BR
Brazil
Prior art keywords
zoniporide
solubility
processes
pharmaceutical compositions
improving
Prior art date
Application number
BR0307195-2A
Other languages
English (en)
Inventor
Daniel Ray Arenson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0307195A publication Critical patent/BR0307195A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS DE MESILATO DE ZONIPORIDE E PROCESSOS PARA MELHORAR A SOLUBILIDADE DO ZONIPORIDE". A presente invenção refere-se a uma composição farmacêutica compreendendo zoniporide (N-(5-ciclopropil-1-quinolin-5-il-1H-pirazol-4-carbonil)quanidina) ou um sal de mesilato da mesma, na presença de um diluente aquoso, em uma faixa de pH de 2 a 3,5. A composição é um inibidor de permutador-1 de hidrogênio de sódio (NHE-1) para a prevenção de, entre outros, lesão isquêmica miocárdica peri-operatório em mamíferos e um processo para aumentar a solubilidade do referido inibidor com ácido metanossulfónico.
BR0307195-2A 2002-01-30 2003-01-20 Composições farmacêuticas de mesilato de zoniporide e processos para melhorar a solubilidade do zoniporide BR0307195A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35302502P 2002-01-30 2002-01-30
PCT/IB2003/000146 WO2003064409A1 (en) 2002-01-30 2003-01-20 Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide

Publications (1)

Publication Number Publication Date
BR0307195A true BR0307195A (pt) 2004-11-03

Family

ID=27663165

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307195-2A BR0307195A (pt) 2002-01-30 2003-01-20 Composições farmacêuticas de mesilato de zoniporide e processos para melhorar a solubilidade do zoniporide

Country Status (16)

Country Link
US (1) US20030149075A1 (pt)
EP (1) EP1472242A1 (pt)
JP (1) JP2005521670A (pt)
AR (1) AR038322A1 (pt)
BR (1) BR0307195A (pt)
CA (1) CA2472342A1 (pt)
DO (1) DOP2003000569A (pt)
GT (1) GT200300012A (pt)
HN (1) HN2003000050A (pt)
MX (1) MXPA04006615A (pt)
PA (1) PA8564501A1 (pt)
PE (1) PE20030817A1 (pt)
SV (1) SV2004001470A (pt)
TW (1) TW200302721A (pt)
UY (1) UY27624A1 (pt)
WO (1) WO2003064409A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2895370T3 (es) * 2017-08-25 2022-02-21 Pfizer Formulación farmacéutica acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin-1-il]carbonil}fenil)-3-[4-(4,6- dimorfolin-4-il-1,3,5-triazin-2-il)fenil]urea

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9908332A (pt) * 1998-02-27 2000-11-07 Pfizer Prod Inc Derivados de n-[carbonil(anel di ou triaza diinsaturado de cinco membros substituìdo)] derivados de guanidina para tratamento de esquemia
UA72002C2 (en) * 1999-10-29 2005-01-17 Pfizer Prod Inc Inhibitors crystals of sodium-hydrogen exchange of 1 type, a method for the preparation thereof (variants), a pharmaceuticalcomposition based thereon and a method for the reduction of tissue damage

Also Published As

Publication number Publication date
SV2004001470A (es) 2004-05-07
PA8564501A1 (es) 2003-09-17
MXPA04006615A (es) 2004-10-04
EP1472242A1 (en) 2004-11-03
AR038322A1 (es) 2005-01-12
JP2005521670A (ja) 2005-07-21
US20030149075A1 (en) 2003-08-07
GT200300012A (es) 2003-08-28
TW200302721A (en) 2003-08-16
DOP2003000569A (es) 2003-08-15
WO2003064409A1 (en) 2003-08-07
PE20030817A1 (es) 2003-10-04
CA2472342A1 (en) 2003-08-07
UY27624A1 (es) 2003-08-29
HN2003000050A (es) 2003-08-22

Similar Documents

Publication Publication Date Title
BR0313723A (pt) Derivados de benzotiazol tendo atividade de agonista beta-2-adrenorreceptor
BRPI0409624A (pt) 2-hidróxi-3-diaminoalcanos de benzamida
TWI348371B (pt)
ATE252572T1 (de) 5-ht1f agonisten
AR051965A1 (es) Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida
BRPI0612072A2 (pt) inibidores da aspartil protease
BRPI0408369A (pt) derivados de indol úteis para o tratamento de doenças
SV2003000727A (es) Agonistas del receptor alfa activado del proliferador de peroxisomas ref. x-14174
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
HRP20050663A2 (en) Malonamide derivatives as gamma-secretase inhibitors
BR0210384A (pt) Heteroarilas multicìclicas substituìdas por quinuclidinas para o tratamento de doença
BR0108893B1 (pt) composiÇço farmacÊutica contendo derivados de azetidina, composto derivado de azetidina, e, processo para a preparaÇço de compostos.
BRPI0308495B8 (pt) composto piridinoila útil para a ativação de receptores 5-ht1f, formulação farmacêutica, e, uso de um composto
BR0212477A (pt) 7-aza[2.2.1] bicicloheptanos substituìdos para o tratamento de doenças
BR0112582A (pt) Sulfonamidas de ciclilamina como agonistas de receptores beta-3 adrenérgicos
BRPI0409627A (pt) 2-hidróxi-3-diaminoalcanos de fenacila
BR0213760A (pt) Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
UY26851A1 (es) Derivados de la 4-fenilpiridina
BR0316629A (pt) Uréias e carbamatos substituìdos
BR0307782A (pt) Compostos azabiciclo para o tratamento de doença
ECSP045469A (es) El uso de cianopirrolidinas sustituidas y preparaciones de combinacion que las contienen para tratar hiperlipidemia y enfermedades asociadas
ATE377000T1 (de) 5-ht1f agonisten
DE69922594D1 (de) Indazol-Derivate als 5-HT1F agonists
BR0215067A (pt) Piridoquinoxalinas antivirais
ATE434605T1 (de) Inhibitoren des serotonintransporters (sert)

Legal Events

Date Code Title Description
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]